Child with SARS-CoV-2 infection and acute lymfoblastic leukemia

Raluca Bontea,Nicoleta Voicu,Simin-Aysel Florescu,Dana Ispas,Cristina Iordache,Gabriela Scurtu,Andreea Popică,Andreea Florentina Stoenescu ,G Vancea ,Null Author_Id ,Claudia Chirilă ,Nicoleta Tudor ,Emanoil Ceauşu ,Petre Iacob Calistru

doi:10.37897/rjid.2021.3.8

Abstract

Introduction. Coronavirus disease 2019 (COVID-19) frequently leads to asymptomatic or mild infectious disease evolution in children. Case presentation. We present the case of a 3 year old girl, known with acute lymphoblastic leukemia in chemotherapy treatment at that time. She had an asymptomatic form of COVID-19 but with important paraclinical changes. The evolution was favorable under the treatment initiated with antibiotics, corticotherapy, gastric protector and symptomatic treatment if necessary. Conclusion. Management of children with COVID-19 and other comorbidities remains a challenge given the few data currently in the literature.

Highlights

INTRODUCTIONFirst appearing in Wuhan, China, in December 2019, SARS-CoV-2 virus infection has spread rapidly to all continents
Coronavirus disease 2019 (COVID-19) frequently leads to asymptomatic or mild infectious disease evolution in children
The signs and symptoms of the disease are comparable to those of adults with a predominance of mild and even asymptomatic forms of the disease [1,2]. It appears that SARS-CoV-2 infection does not present a higher risk of respiratory complications in immunosuppressed patients, destruction of lung tissue during infection depends on the host’s immune response [3]

Summary

INTRODUCTION

First appearing in Wuhan, China, in December 2019, SARS-CoV-2 virus infection has spread rapidly to all continents. It appears that SARS-CoV-2 infection does not present a higher risk of respiratory complications in immunosuppressed patients, destruction of lung tissue during infection depends on the host’s immune response [3]. The background treatment was stopped about a week before hospitalization at the indication of the hematologist who observed in the routine tests of the patient leukopenia with neutropenia. The clinical and paraclinical evolution of the child was good, the radiological and biological investigations returning to normal during the 10-day hospitalization. The child was able to resume the treatment of the underlying disease after discharge. He was monitored by his family doctor and his hematologist specialist

DISCUSSION

CONCLUSIONS